Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PIPERACILLIN SODIUM & TAZOBACTAM SODIUM

All injection strengths: not a benefit

Other products in the same Health Canada class (J01C, J01CR) — coverage varies; not interchangeable

  • Amoxicillin + clavulanic acid (Clavulin): general benefit, Not a benefit
  • Amoxicillin (Novamoxin): general benefit, Not a benefit, Listing status unconfirmed
  • Ampicillin (Penbritin): general benefit, Not a benefit
  • Cloxacillin (Orbenin): general benefit, Not a benefit
  • Penicillin v (Nadopen-V): general benefit, Not a benefit

Piperacillin and Tazobactam for Inj · DIN 02401339 · 4g & 500mg · injection Pd-4.5g vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-06-02 — choose a marketed DIN from the same-category list.Discontinued 2022-06-02 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-06-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-06-02 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Piperacillin and Tazobactam for Inj · DIN 02401339 Manufacturer: Teligent OU; listing date 2018-11-29 Health Canada: Cancelled post market since 2022-06-02 · brand PIPERACILLIN AND TAZOBACTAM FOR INJECTION · ATC J01CR05 PIPERACILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for solution · route Intravenous · ingredients PIPERACILLIN (PIPERACILLIN SODIUM) 4 G/VIAL, TAZOBACTAM (TAZOBACTAM SODIUM) 0.5 G/VIAL · company Hikma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Piperacillin and Tazobactam for Inj: Formulary list price $20.2700/unit (unit not stated in source; not the patient's cost)

Ministry pays: $20.2700 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88625 · Verify on the e-Formulary ↗ (DIN 02401339)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02401339). DIN 02401339: Piperacillin and Tazobactam for Inj Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081216102; group id 30; item number 0064; lccId None; manufacturer id TEL Source form: Inj Pd-4.5g Vial Pk; strength: 4g & 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $20.2700; ministry $20.2700 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02401339 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88625
Interchangeable products
Piperacillin & Tazobactam For Injection · DIN 02402084 · $20.2700 Piperacillin & Tazobactam for Injection · DIN 02308460 · $20.2700 Piperacillin & Tazobactam for Injection · DIN 02362635 · $20.2700 Piperacillin/Tazobactam powder for Inj. · DIN 02370174 · $20.2700 Tazocin · DIN 02170809 · not recorded
Shortage status: resolved shortage (ended 2022-07-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02401339
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-06-02 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:16 Penicillins) and how they are covered

Matched class: 08:12:16 Penicillins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AMOXICILLIN, AMOXICILLIN & CLAVULANIC ACID, AMPICILLIN, CLOXACILLIN, PENICILLIN V (POTASSIUM) 08:12:16 Penicillins

AMOXICILLIN & CLAVULANIC ACID

· 25 products · General benefit (22), Listed, not a benefit (3) · strengths: 25mg & 6.25mg/mL, 50mg & 12.5mg/mL, 200mg & 28.5mg/5mL, 400mg & 57mg/5mL, 250mg & 125mg, 500mg & 125mg, 875mg & 125mg · O/L, Susp, Tab

AMOXICILLIN

· 36 products · General benefit (27), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (4), Temporary benefit (1) · strengths: 250mg, 500mg, 125mg, 25mg/mL, 50mg/mL · Cap, Chew Tab, O/L, Pd for Oral Susp

AMPICILLIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 250mg, 500mg · Cap

CLOXACILLIN

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 250mg, 500mg, 25mg/mL · Cap, O/L

PENICILLIN V (POTASSIUM)

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg/mL, 300mg · O/L, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:16
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Piperacillin and Tazobactam for Injection (sterile piperacillin sodium / tazobactam sodium) is indicated for the treatment of patients with systemic and / or local bacterial infections, caused by piperacillin resistant, piperacillin / tazobactam susceptible, ß-lactamase producing strains of the designated microorganisms in the specified conditions listed below: a) INTRA-ABDOMINAL INFECTIONS Appendicitis (complicated by rupture or abscess) and peritonitis caused by piperacillin resistant, ß-lactamase producing strains of Escherichia coli or members of the Bacteroides fragilis group. b) SKIN AND SKIN STRUCTURE INFECTIONS Uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscess, acute ischemic / diabetic foot infections caused by piperacillin resistant ß-lactamase producing strains of Staphylococcus aureus (not methicillin-resistant strains). c) GYNECOLOGICAL INFECTIONS Postpartum endometritis or pelvic inflammatory disease caused by piperacillin resistant, ß - lactamase producing strains of Escherichia coli. d) COMMUNITY-ACQUIRED LOWER RESPIRATORY TRACT INFECTIONS… https://pdf.hres.ca/dpd_pm/00078136.PDF PM date: DEC 24, 2024 Source product: PIPERACILLIN AND TAZOBACTAM FOR INJECTION; DIN 02362619; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Piperacillin and Tazobactam for Inj: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026